# NAD+: the molecule whose legal category is argued over more than its biology > NAD+: Research Overview — Buy Canadian Peptides — NAD+ within Research Peptide Fundamentals research peptides: a coenzyme, not a peptide, whose precursor trials reliably raise blood NAD+ while its legal category remains actively disputed. What the human evidence establishes, and what it does not. **02 / NAD+ — A CONTESTED CATEGORY** A coenzyme every cell already makes, sold as a supplement, infused in clinics, and caught in a regulatory argument about what counts as a supplement in the first place. ## The short version NAD+ is not a peptide. It is a coenzyme — a small helper molecule that every living cell already manufactures and that sits at the centre of how cells turn food into usable energy. It is on this desk anyway, because it travels in the same conversations as the peptides here and because its legal position is the most tangled of the four. Tissue levels of NAD+ fall with age, which is the reason anyone tries to top them up. Swallowing NAD+ itself works poorly, so the research uses precursors — nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) — that cells can convert. Those precursors do reliably raise NAD+ in blood: one trial measured whole-blood increases of 22%, 51% and 142% across ascending amounts over eight weeks [10]. What has not been shown is that raising the number changes anything that matters over a lifetime. A 2025 review of the human evidence concluded that trials so far have shown limited efficacy and that the data on tissue-level NAD+ remain sparse [6]. The biology is solid; the payoff is unproven. ## What it is NAD+ is nicotinamide adenine dinucleotide: a dinucleotide built from nicotinamide mononucleotide and adenosine monophosphate joined by two bridging phosphate groups, carrying a pyridine nicotinamide ring and an adenine ring, with the molecular formula C21H27N7O14P2. It exists in an oxidised form, NAD+, and a reduced form, NADH, and the ratio between them is one of the cell's fundamental settings. In older literature it appears as coenzyme I or DPN, diphosphopyridine nucleotide. The two precursors that dominate the research — NMN and NR — are separate molecules that the cell converts into NAD+ through its salvage pathway. That distinction matters commercially and legally as well as biochemically, because the three are regulated as three different things even though the research treats them as three routes to one endpoint. The practical consequence, and a live argument in the field, is that oral NAD+ itself is poorly taken up by cells intact. Most researchers consider the precursors the rational oral approach, and some argue that plain oral NAD+ capsules are largely ineffective. ## How it works NAD+ does two jobs that pull in opposite directions, and most of the interesting biology sits in the tension between them. The first is redox chemistry. NAD+ carries electrons through glycolysis, the TCA cycle and oxidative phosphorylation, which is how cells make ATP. In that role it is recycled rather than used up. The second is signalling, and here it is *consumed*. A set of enzymes — the sirtuins (SIRT1 through SIRT7), the PARPs (chiefly PARP1, the DNA-damage responder) and the ectoenzymes CD38 and CD157 — cleave NAD+ as a substrate while regulating DNA repair, gene expression and inflammation. Those enzymes compete for a shared pool [9]. Ageing tilts that competition. Tissue NAD+ declines, partly because CD38 activity rises with age and inflammation, drawing down the pool that the sirtuins and PARPs also need. NAMPT, the rate-limiting enzyme of the salvage pathway, sets how fast the pool can be refilled. The foundational review that mapped these consuming enzymes framed restoring NAD+ as a candidate strategy against age-related disease [9] — a hypothesis about a mechanism, and the origin of everything sold on the back of it. ## What the research shows The human trials divide cleanly into what they measured and what they merely hoped for. **Raising the number is established.** In healthy overweight adults, NR taken at ascending amounts across a 100 to 1000 mg per day range for eight weeks raised whole-blood NAD+ by 22%, 51% and 142% respectively, with no flushing and no significant difference in adverse events from placebo at any amount [10]. In a multicentre double-blind randomised trial in middle-aged adults, oral NMN at 300 to 900 mg per day for sixty days raised blood NAD+ in a dose-dependent way; the trial also reported improved walking distance and quality-of-life scores against placebo and identified 600 mg per day as the optimal amount, with no safety issues at any level tested [7]. **One functional result stands out.** Ten weeks of oral NMN at 250 mg per day improved muscle insulin sensitivity and remodelled insulin signalling in prediabetic postmenopausal women [8]. It is a small, specific, mechanistically coherent finding in a defined population. **The overall verdict is unsettled.** A 2025 narrative review of the human clinical evidence on NAD+ precursor supplementation in ageing concluded that trials have shown limited efficacy, that the age-related decline in NAD+ has been consistently observed in only a limited number of human studies, and that data on tissue-specific NAD+ dynamics remain sparse — with an explicit call for more clinical work rather than continued extrapolation from rodents [6]. That gap between a well-demonstrated biomarker change and an unproven clinical benefit is the single most important thing to carry away from the NAD+ literature. The amounts described above are what the trials administered, recorded here as study design; nothing on this page recommends an amount for anyone. ## Cautions and open questions There is no community-reported effects register for NAD+ in the audited source material behind this site, and no formally documented safety-caution set of the kind the peptides here carry. What exists instead is a set of open disputes, and they are worth reading in full. - **Oral NAD+ itself is poorly absorbed intact.** The precursor route is the one the research supports; plain oral NAD+ capsules are argued by some researchers to be largely ineffective. - **The biomarker is not the outcome.** Raising blood NAD+ is well demonstrated [10] [7], but translation into hard clinical endpoints — longevity, disease prevention — remains unproven in humans [6]. - **Most of the strongest anti-ageing data come from rodents** and may not extrapolate. - **Intravenous NAD+ wellness therapy is marketed far ahead of its evidence.** Infused NAD+ is rapidly cleared from plasma, and infusions can cause chest or abdominal discomfort, flushing and nausea if run too quickly. - **Compounded injectable NAD+ carries a contamination risk.** The FDA has issued a Class I recall of a compounded NAD+ injection for elevated bacterial endotoxin — a contamination event that belongs to the compounded rather than the approved pathway. - **A theoretical oncology concern exists.** NAD+ supports proliferating cells, and its roles in cancer are dual and context-dependent, so caution is advised in cancer populations. - **Supplement-grade product quality varies.** Purity and actual content differ between products, and third-party testing is not guaranteed. - **The regulatory status of NMN is contested.** The FDA has taken the position that NMN is excluded from the dietary-supplement definition because it was investigated as a drug, which has created ongoing marketplace uncertainty. In sport, NAD+ and its precursors — NMN, NR and nicotinamide — are not prohibited by the World Anti-Doping Agency. ## Where it sits on the jurisdictional map NAD+ is the clearest case on this desk of a molecule whose legal identity is decided by something other than its chemistry. The contest over NMN turns on a rule about regulatory history. The FDA's position is that NMN is excluded from the dietary-supplement definition because it was investigated as a drug first — that is, the sequence in which two filings happened determines whether a substance may be sold as a supplement. Nothing about the molecule participates in that decision. A different country, applying a differently drafted supplement statute, could reach a different conclusion about the same white powder without disagreeing about a single fact of biochemistry. The injectable and intravenous forms sit in a second regulatory lane again. They are typically compounded rather than approved, which means the product a person receives is prepared under compounding rules rather than manufactured under an approved marketing authorisation. That distinction is why an endotoxin recall arises in this category at all — and it is a distinction that exists in some form in most national frameworks, though the details, the permitted preparations and the oversight differ everywhere. So NAD+ can be, simultaneously and legitimately: a dietary supplement, a substance whose precursor is contested as a supplement, a compounded injectable, and an unregulated ingredient in a wellness clinic's infusion. Which of those a reader encounters depends almost entirely on where they are standing. What does not change with location is the evidence: the precursor trials cited on this page were run once, and every regulator that has an opinion is reading the same ones. --- Buy Canadian Peptides is a citation-indexed reading desk on how different countries categorise the same molecules — it sells nothing, names no seller in any jurisdiction, and treats a gap between two regulators as a fact to explain rather than an offer to make.